Janssen Earlier Announced TAR-200 Intravesical Delivery System Results Show 77% Complete Response Rate In Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer
Portfolio Pulse from Charles Gross
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, announced positive results from the Phase 2b SunRISe-1 study of TAR-200 monotherapy for high-risk non-muscle-invasive bladder cancer. The study showed a 77% complete response rate in patients, with sustained responses beyond one year.
October 22, 2023 | 3:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's subsidiary Janssen reported positive results from a Phase 2b study of TAR-200, potentially boosting the company's oncology portfolio.
Positive clinical trial results often lead to increased investor confidence and potential stock price increases. The successful Phase 2b study of TAR-200 strengthens J&J's oncology portfolio, potentially leading to future revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100